Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
SANTA ANA, Calif. - NKGen Biotech, Inc. (OTC:NKGN), a clinical-stage biotechnology company with a current market capitalization of $9.9 million, announced that its Chairman and CEO Paul Y. Song will present at the 3rd China Great Bay Cell and Gene Therapy Forum in Guangzhou on September 25-26, 2025. According to InvestingPro data, the company’s shares have declined nearly 80% year-to-date.
Dr. Song’s presentation will focus on troculeucel, the company’s investigational autologous enhanced natural killer (NK) cell therapy being developed for neurodegenerative diseases. He will discuss the scientific rationale and recent clinical data supporting the treatment approach.
The presentation, titled "Use of Troculeucel for Neurodegenerative Diseases - Scientific Rationale and Latest Clinical Data," is scheduled for September 25 at 3:20 PM China Standard Time at the Sino-Singapore Guangzhou Knowledge City International Convention and Exhibition Center.
The forum is expected to attract over 1,200 experts and feature more than 90 speakers from across the cell and gene therapy sector.
Troculeucel is a patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate that NKGen is developing for neurodegenerative disorders and various cancers. The therapy recently received its International Nonproprietary Name from the World Health Organization.
NKGen Biotech is a clinical-stage biotechnology company focused on developing NK cell therapeutics, with headquarters in Santa Ana, California.
The company stated that a copy of the presentation will be made available on its website after the event concludes, according to the press release statement.
In other recent news, NKGen Biotech has made several notable advancements with its cell therapy, troculeucel. The U.S. Food and Drug Administration (FDA) has approved an Expanded Access Program for troculeucel, allowing up to 20 patients with various neurodegenerative diseases to receive the treatment. This includes conditions such as early-stage Alzheimer’s, Parkinson’s, and ALS, among others. Additionally, NKGen Biotech has formed a strategic partnership with Tokyo-based HekaBio to advance troculeucel’s development in Japan. Under this partnership, HekaBio will spearhead clinical trials and regulatory activities with the aim to start dosing Japanese patients within the next year. Furthermore, NKGen has administered the first dose of troculeucel to a patient with mild-stage Alzheimer’s disease under a compassionate use authorization from the FDA. This treatment is being conducted in collaboration with Dr. Anita Fletcher at AdventHealth Neuroscience Institute. These recent developments highlight NKGen’s efforts to expand the reach and application of its cell therapy in treating neurodegenerative diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.